Treatment of COVID-19-associated ARDS with umbilical cord-derived mesenchymal stromal cells in the STROMA-CoV-2 multicenter randomized double-blind trial: long-term safety, respiratory function, and quality of life.
Alexandre SitbonCaroline Hauw-BerlemontMiryam MebarkiNicholas HemingJulien MayauxJean-Luc DiehlAlexandre DemouleDjillali AnnaneClémence MaroisSophie DemeretEmmanuel WeissGuillaume VoiriotMuriel FartoukhJean-Michel ConstantinBruno MégarbaneGaëtan PlantefèveHélène Boucher-PilletGuillaume ChurlaudAudrey CrasCamille MaheuxChloé PezzanaMamadou Hassimiou DialloSaid LebbahJacques RopersJoe-Elie SalemChristian StrausPhilippe MenaschéJérôme LargheroAntoine Monselnull nullPublished in: Stem cell research & therapy (2024)
This study suggests a favorable safety profile for the use of intravenous UC-MSCs in the context of the first French wave of SARS-CoV-2-related moderate-to-severe acute respiratory distress syndrome, with no adverse effects observed at 1 year.
Keyphrases
- acute respiratory distress syndrome
- sars cov
- double blind
- umbilical cord
- mesenchymal stem cells
- phase iii
- placebo controlled
- extracorporeal membrane oxygenation
- respiratory syndrome coronavirus
- phase ii
- clinical trial
- mechanical ventilation
- study protocol
- open label
- bone marrow
- coronavirus disease
- high dose
- randomized controlled trial
- intensive care unit
- high intensity
- drug induced
- low dose
- smoking cessation